Ignite Creation Date:
2024-05-06 @ 8:03 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06230562
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-01-30
First Post:
2024-01-09
Brief Title:
DIAGALS Relation Between Tar DNA Binding ProteinTDP-43 et Nrf-2 in ALS a Track to Improve Diagnosis and Prognosis of the Disease
Sponsor:
University Hospital Tours
Organization:
University Hospital Tours
Study Overview
Official Title:
DIAGALS Relation Between TDP-43 et Nrf-2 in ALS a Track to Improve Diagnosis and Prognosis of the Disease Prospective Bicentric Non-randomized Open-label Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DIAGALS
Brief Summary:
In response to oxidative stress cells activate the Nrf-2 pathway which induces translation of its target genes and corresponding proteins involved in the antioxidant response This explains the interest in the Nrf-2 pathway in the pathophysiology of Amyotrophic lateral sclerosis ALS supported by the results of several studies and the modulatory effect of TDP-43 on the Nrf-2 pathway Since both TDP-43 and Nrf-2 proteins are present in the peripheral blood mononuclear cells PBMC of ALS patients and may be correlated with disease progression the investigators wish to explore their relationship and their application in the clinic as potential blood biomarkers for ALS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None